AI assistant
Sending…
Immunome Inc. — Director's Dealing 2021
Jun 22, 2021
32238_dirs_2021-06-21_54681249-a4c5-4c10-be97-488da14d2b8d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Immunome Inc. (IMNM)
CIK: 0001472012
Period of Report: 2021-06-16
Reporting Person: PRENDERGAST FRANKLYN G (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-16 | Stock Option (Right to Buy) | $16.96 | A | 7500 | Acquired | 2031-06-16 | Common Stock (7500) | Direct |
Footnotes
F1: The shares subject to the option shall vest one-twelfth (1/12th) every quarter after the grant date.
More from Immunome Inc.
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Annual Report
2026
Mar 3
Earnings Release
2026
Mar 3
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2025
Dec 31
Director's Dealing
2025
Dec 23
Major Shareholding Notification
2025
Dec 23